ProVac: Evidence-Based Decision on New Vaccines
The initiative began in 2006 under the leadership of PAHO, focusing primarily on four new vaccines, namely rotavirus, pneumococcal, influenza, and HPV. These vaccines are relatively new, and more costly than traditional childhood vaccines; Ministries of Health must make difficult budgetary decisions on which vaccines are feasible, affordable, and cost-effective – as well as decision making criteria focused on regional concerns as opposed to national or sub-national interests.
The Center has and will continue to play an important role within this initiative, utilizing its strengths in developing models of vaccine-preventable diseases, conducting economic evaluations, and assessing strategies for vaccine delivery. The Center lends particular expertise with regard to HPV vaccines to prevent cervical cancer.
The goal is not to conduct evaluations for the participating countries, rather to serve as active partners and provide technical assistance when needed. Project members guide countries in gathering data and developing decision-making standards to build a base for comprehensive economic evaluation. These evaluations inform decisions regarding which vaccine introductions are viable and at what pace an introduction should be orchestrated. The ultimate goal is to enable country capability to make vaccine introduction decisions on the basis of robust evidence-based analysis.